Repeatability of and Relationship between Potential COPD Biomarkers in Bronchoalveolar Lavage, Bronchial Biopsies, Serum, and Induced Sputum

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Röpcke, Stefan ^a   Holz, Olaf ^b,c   Lauer, Gereon ^a   Müller, Meike ^b   Rittinghausen, Susanne ^b   Ernst, Peter ^d   Lahu, Gezim ^a   Elmlinger, Martin ^a   Krug, Norbert ^b,c   Hohlfeld, Jens M ^b,c  

^a Nycomed GmbH   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^c Member of the German Center for Lung Research   (Germany)

^d GENEDATA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA INTERFERON; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CREATININE; EOTAXIN; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LEPTIN; PLATELET DERIVED GROWTH FACTOR AA; SEROTONIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN TISSUE; LUNG LAVAGE; MALE; NEUTROPHIL; RESPIRATORY TRACT INFLAMMATION; SERUM; SMOKING; SPUTUM; VALIDITY;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; C-REACTIVE PROTEIN; CYTOKINES; DESMOSINE; FEMALE; HUMANS; INTERLEUKIN-6; ISODESMOSINE; LUNG; MALE; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SPUTUM; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84867116844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046207     Document Type: Article

References (36)

1. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, et al. (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31: 416-469.
2. Petty TL, (2002) COPD in perspective. Chest 121: 116S-120S.
3. Crapo JD, (2010) Preclinical vascular disease identifies smokers at risk for COPD. Proc Natl Acad Sci U S A 107: 8503-8504.
4. Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, et al. (2008) Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178: 1211-1218.
5. [Anonymous] (2010) From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010.-Available: http://www.goldcopd.com/. Accessed: September 6th, 2012).
6. Cazzola M, Novelli G, (2010) Biomarkers in COPD. Pulm Pharmacol Ther 23: 493-500.
7. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, et al. (2006) Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174: 6-14.
8. Tzortzaki EG, Lambiri I, Vlachaki E, Siafakas NM, (2007) Biomarkers in COPD. Curr Med Chem 14: 1037-1048.
9. Vestbo J, Rennard S, (2010) Chronic obstructive pulmonary disease biomarker(s) for disease activity needed-urgently. Am J Respir Crit Care Med 182: 863-864.
10. Jörres RA, Welte T, Bals R, Koch A, Schnoor M, et al. (2010) [Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease-an overview of the cohort study COSYCONET]. Dtsch Med Wochenschr 135: 446-449.
11. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, et al. (2008) Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 31: 869-873.
12. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, et al. (2011) COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 12: 146 1465-9921-12-146 [pii];10.1186/1465-9921-12-146 [doi].
13. Sin DD, Vestbo J, (2009) Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc 6: 543-545.
14. Anderson GP, (2006) COPD, asthma and C-reactive protein. Eur Respir J 27: 874-876.
15. Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH, (2007) Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc 4: 626-634.
16. Kolsum U, Roy K, Starkey C, Borrill Z, Truman N, et al. (2009) The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis 4: 149-156.
17. Watz H, Waschki B, Kirsten A, Müller KC, Kretschmar G, et al. (2009) The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 136: 1039-1046.
18. Singh D, Edwards L, Tal-Singer R, Rennard S, (2010) Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 11: 77.
19. Aaron SD, Vandemheen KL, Ramsay T, Zhang C, Avnur Z, et al. (2010) Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res 11: 41.
20. de Torres JP, Casanova C, Pinto-Plata V, Varo N, Restituto P, et al. (2011) Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study. PLoS One 6: e16021.
21. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM, (2006) Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61: 17-22.
22. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, et al. (2008) Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 178: 444-452.
23. Ventetuolo CE, Benza RL, Peacock AJ, Zamanian RT, Badesch DB, et al. (2008) Surrogate and combined end points in pulmonary arterial hypertension. Proc Am Thorac Soc 5: 617-622.
24. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, et al. (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70: 380-385.
25. Polosa R, Malerba M, Cacciola RR, Morjaria JB, Maugeri C, et al. (2011) Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Intern Emerg Med.
26. Polatli M, Cakir A, Cildag O, Bolaman AZ, Yenisey C, et al. (2008) Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 26: 97-102.
27. Lawrence T, Gilroy DW, (2007) Chronic inflammation: a failure of resolution? Int J Exp Pathol 88: 85-94.
28. Hernandez ML, Harris B, Lay JC, Bromberg PA, Diaz-Sanchez D, et al. (2010) Comparative airway inflammatory response of normal volunteers to ozone and lipopolysaccharide challenge. Inhal Toxicol 22: 648-656.
29. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, et al. (2006) Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174: 867-874.
30. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, et al. (1996) Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 154: 308-317.
31. Grootendorst DC, Sont JK, Willems LN, Kluin-Nelemans JC, Van Krieken JH, et al. (1997) Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy 27: 769-779.
32. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, et al. (2012) Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 7: e37483 10.1371/journal.pone.0037483 [doi];PONE-D-12-05051 [pii].
33. Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, et al. (2006) Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 114: 1655-1661.
34. Beirne P, Pantelidis P, Charles P, Wells AU, Abraham DJ, et al. (2009) Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur Respir J 34: 1376-1382.
35. Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, et al. (2005) Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol 45: 498-503.
36. Fleiss JL (1986) Design and Analysis of Clinical Experiments. New York: 13 p.